Presentations & Publications

PRESENTATION · Jul 2025 · PDF

ADH1 - ENDO 2025 - Baseline Characteristics of Pediatric Participants in the CLARIFY Disease Monitoring Study

PRESENTATION · Jul 2025 · PDF

Encaleret - ADH1 - ENDO 2025 - Phase 2 Over 42 Months Data Results

PRESENTATION · Jul 2025 · PDF

Encaleret - ADH1 - ENDO 2025 - CALIBRATE-PEDS Phase 2/3 Study Design

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ASBMR 2024 Phase 2B Data over 24 Months

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ASBMR 2024 Preliminary Findings from Ongoing Open Label Phase 2 Study

PRESENTATION · Dec 2024 · PDF

ADH1 - ENDO 2024 Characteristics of Adults with ADH1 enrolled in CLARIFY

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ACMG 2024 Genetic Testing

PRESENTATION · Dec 2023 · PDF

ADH1 - ASHG 2023 Novel Variants of the CaSR

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ASBMR 2023 Mineral Normalization in Phase 2b

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ASBMR 2023 CALIBRATE Phase 3 Study Design

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ENDO 2023 18 Month Phase 2b Data

PRESENTATION · Dec 2023 · PDF

ADH1 - ENDO 2023 Preliminary Results from Genetic Testing Program

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ESE 2023 12 Month Phase 2b Data

PUBLICATION · Sep 2023

The New England Journal of Medicine, Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1

PUBLICATION · Oct 2022 · PDF

Journal of Bone and Mineral Research, Autosomal Dominant Hypocalcemia Type 1: A Systematic Review